Displaying drugs 7851 - 7875 of 8195 in total
Allocetra
Allocetra is a novel therapy where billions of early apoptotic cells are infused into the bloodstream of a patient, using the body's own natural regulation mechanisms to rebalance an unbalanced immune system without immune system suppression. With infusion, the body's macrophages and dendritic cells can feed on these early apoptotic...
Investigational
Matched Description: … Allocetra is a novel therapy where billions of early apoptotic cells are infused into the bloodstream ... of a patient, using the body's own natural regulation mechanisms to rebalance an unbalanced immune system …
Pyruvaldehyde
An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. [PubChem]
Experimental
Matched Description: … It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated …
L-cysteic acid
L-cysteic acid is a beta-sulfoalanine. It is an amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate. It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather.
Experimental
Matched Description: … It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather …
Sonepcizumab
A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).
Investigational
Matched Description: … Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis …
NGN-401
NGN-401 is a recombinant serotype 9 adeno-associated virus (AAV) encoding an intron encoding a miRNA generating sequence, complementary miRNA binding sites and a full-length human methyl cytosine binding protein 2 (MECP2). Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.
Investigational
Matched Description: … ., it is being investigated for the treatment of Rett syndrome. …
MF101
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
Matched Description: … MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and …
GT 389-255
Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase I trials. It is expected to block fat absorption with fewer side effects than currently marketed lipase...
Investigational
Matched Description: … GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of …
RO7284755
RO7284755 is an investigational cancer drug: it is a PD-1-targeted IL-2 variant antibody fusion protein. RO7284755 is under investigation in clinical trial NCT04303858 (A Study to Evaluate Safety and Anti-tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced And/or Metastatic Solid Tumors).
Investigational
Matched Description: … under investigation in clinical trial NCT04303858 (A Study to Evaluate Safety and Anti-tumor Activity of …
Sonpiretigene isteparvovec
Sonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy. Developed by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP). Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks.
Investigational
Matched Description: … [L46676] Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three …
D-Glutamine
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
Experimental
Matched Description: … It is the principal carrier of nitrogen in the body and is an important energy source for many cells. …
Zebularine
A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.
Experimental
Matched Description: … It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as …
IR208
IR208 is a synthetic T-Cell receptor peptide
vaccine developed by Immune Response Corporation.
It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients. IR208 is currently undergoing Phase II
studies in a 200-patient trial.
Investigational
Matched Description: … It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients …
Pimagedine
Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.
Investigational
Matched Description: … Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease …
IMC-1C11
IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
Investigational
Matched Description: … IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma. …
Selisistat
Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.
Experimental
Matched Description: … Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase …
AdimrSC-2f
The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia . A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548].
Investigational
Matched Description: … A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548 …
beta-Alanine
beta-Alanine is an amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported.
Experimental
Matched Description: … beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine]. …
Budigalimab
Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
Investigational
Matched Description: … NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of …
AVR-RD-01
AVR-RD-01 is an investigational ex vivo lentiviral gene therapy developed by AVROBIO Inc. It consists of autologous CD34+ cells that transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence. AVR-RD-01 is being investigated for Fabry Disease.[L45963, L45968]
Investigational
Matched Description: … It consists of autologous CD34+ cells that transduced with Lentiviral Vector/alpha-galactosidase A (AGA …
Elinzanetant
Elinzanetant is under investigation in clinical trial NCT05099159 (A Study to Learn More About How Well Elinzanetant Works and How Safe It Is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)).
Investigational
Matched Description: … NCT05099159 (A Study to Learn More About How Well Elinzanetant Works and How Safe It Is for the Treatment of …
Binodenoson
Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A2A receptor. This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a...
Investigational
Matched Description: … This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication …
AN-9
Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo. It shows greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties than BA...
Investigational
Matched Description: … Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low …
5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole
5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. Known drug targets of 5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole include genome polyprotein.
Experimental
Matched Description: … Known drug targets of 5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole include genome …
Gam-COVID-Vac
Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is offered in both...
Investigational
Matched Description: … Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. ... Phase 1/2 human trials with 76 participants evaluated the safety, tolerability, and immunogenicity of …
Satraplatin
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
Investigational
Matched Description: … Satraplatin is a platinum compound that is currently under investigation as one treatment of patients …
Displaying drugs 7851 - 7875 of 8195 in total